IRAK1, a key mediator of TLR/IL-1R signaling, drives tumor cell proliferation and a pro-inflammatory microenvironment when aberrantly activated. Its overexpression has been observed in multiple cancers, including hepatocellular carcinoma (HCC).
China Pharmaceutical University has prepared and tested sphingomyelin phosphodiesterase (SMPD1; aSMase) inhibitors potentially useful for the treatment of cancer, autoimmune disease, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, depression, diabetes, hepatic steatosis and stroke, among others.
China Pharmaceutical University and Chongqing Innovation Institute China Pharmaceutical University have reported tetrahydronaphthyridine compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists.
Myopia is a refractive disorder caused by excessive axial elongation, leading to blurred distance vision. Its development involves genetic, environmental and molecular factors, including retinal N6-methyladenosine (m6A) RNA modification.
NF-κB-inducing kinase (NIK), also known as MAP3K14, is the key kinase driving noncanonical NF-κB signaling and p100 processing. Researchers from China Pharmaceutical University reported the discovery and preclinical evaluation of a novel NIK inhibitor.
Multidrug-resistant (MDR) gram-positive bacteria can evade last-line therapies, such as vancomycin, daptomycin and linezolid, through the development of sophisticated resistance mechanisms that include inactivation of target enzymes, mutations in binding sites, alterations in membrane permeability and overexpression of efflux pumps.
China Pharmaceutical University has synthesized transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, fibrosis, metabolic diseases and inflammatory disorders.
Ascentage Pharma (Suzhou) Co. Ltd. and China Pharmaceutical University have identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker reported to be useful for the treatment of cancer.
China Pharmaceutical University and Chongqing Innovation Institute, China Pharmaceutical University have identified compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, fibrosis, infections, inflammation, autoimmune diseases, metabolic disorders, neurological disorders and cardiovascular disorders, among others.
